Extubation from high-frequency oscillatory ventilation in extremely low birth weight infants: a prospective observational study

Milena Tana,1 Alessandra Lio,1 Chiara Tirone,1 Claudia Aurilia,1 Eloisa Tiberi,1 Francesca Serrao,1 Velia Purcaro,1 Mirta Corsello,1 Piero Catenazzi,1 Vito D’Andrea,1 Giovanni Barone,1 Cinzia Ricci,1 Roberta Pastorino,2 Milena Tana,1 Alessandra Lio,1 Chiara Tirone,1 Claudia Aurilia,1 Eloisa Tiberi,1 Francesca Serrao,1 Velia Purcaro,1 Mirta Corsello,1 Piero Catenazzi,1 Vito D’Andrea,1 Giovanni Barone,1 Cinzia Ricci,1 Roberta Pastorino,2 Giovanni Vento1,3

ABSTRACT

Objective To evaluate if weaning from high-frequency oscillatory ventilation (HFOV) directly to a non-invasive mode of respiratory support is feasible and results in successful extubation in extremely low birth weight (ELBW) infants.

Design Prospective observational study.

Setting Tertiary neonatal intensive care unit.

Patients One hundred and eight ELBW infants of 26.2±1.4 weeks of gestational age (GA) directly extubated from HFOV.

Interventions All infants were managed with elective HFOV and received surfactant after a recruitment HFOV manoeuvre. Extubation was attempted at mean airways pressure (MAP) ≤6 cm H2O with FiO2 ≤0.25. After extubation, all infants were supported by nasal continuous positive airway pressure (6–8 cm H2O).

Main outcome measures Extubation failure (clinical deterioration requiring reintubation) was defined as shorter than 7 days.

Results Ninety patients (83%) were successfully extubated and 18 (17%) required reintubation. No significant differences were found between the two groups in terms of birth weight, day of life and weight at the time of extubation. Multivariable analysis showed that GA (OR 1.71; 95% CI 1.04, 2.08) and higher MAP prior to surfactant (OR 1.51; 95% CI 1.06, 2.15) were associated with successful extubation.

Conclusions In ELBW infants, direct extubation from HFOV at MAP ≤6 cm H2O with FiO2 ≤0.25 is feasible. Our extubation success rate (83%) is higher than conventional mechanical ventilation in this very vulnerable class of infants.

INTRODUCTION

Despite the increased use of non-invasive respiratory support, mechanical ventilation may be life-saving in preterm infants with respiratory failure, especially in extremely low birth weight (ELBW) infants (birth weight<1000g).1 2 A prolonged endotracheal intubation is associated with risks and complications, including bronchopulmonary dysplasia (BPD),1 4 therefore clinicians should wean and extubate ELBW infants as soon as possible.3 Several studies tried to find the optimal timing of extubation of preterm infants treated with conventional mechanical ventilation (CMV).8–14 In these studies, success of extubation in ELBW infants ranged from 52% to 73%,8 14 and this is why extubation failure remains a major problem. In the last years, high-frequency oscillatory ventilation (HFOV) has been increasingly used in preterm infants with respiratory failure,
because early HFOV could reduce risk of BPD.\textsuperscript{15} Especially if associated with an open lung strategy.\textsuperscript{16,17} Despite that, data on weaning and extubation criteria are limited, especially in ELBW infants. Some clinicians are more comfortable in switching from HFOV to CMV to wean and extubate the infants,\textsuperscript{18} but this combined strategy could reduce the efficacy of HFOV alone to decrease the incidence of BPD.\textsuperscript{19} Direct extubation from HFOV is possible and may even be desirable.\textsuperscript{7,16} Van Velzen \textit{et al} showed that weaning the mean airways pressure (MAP) below 8 cm H\textsubscript{2}O with a fraction of inspired oxygen (FiO\textsubscript{2}) below 0.30 is feasible during open lung HFOV and direct extubation at these settings is successful in 90\% of preterm infants<37 weeks of gestational age (GA). However, the success rate dropped to 81\% in 68 ELBW studied infants.\textsuperscript{20} Compared with the experience of van Velzen \textit{et al}, our study is aimed at: the extubation process from HFOV in ELBW infants only (ie, the population at greater risk of ventilator-induced lung injury); evaluating the success or failure of the extubation attempt over a longer period of time (7 days instead of 48 hours after extubation) and the safety of lower pre-extubation MAP values (≤6 cm H\textsubscript{2}O instead of 8 cm H\textsubscript{2}O) as the most appropriate ventilatory set for ELBW neonates.\textsuperscript{13,14} The aim of the present study is therefore to evaluate in a cohort of ELBW infants treated with elective open lung HFOV if MAP≤6 cm H\textsubscript{2}O and FiO\textsubscript{2}≤0.25 are feasible and successfully associated with direct HFOV extubation during a 7-day observation window, as longer periods may be needed to adequately capture this outcome in ELBW infants.\textsuperscript{13,14}

**METHODS**

**Patients**

This study was approved by the Ethics Committee of the Department of Pediatrics of Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma—Università Cattolica del Sacro Cuore, which waived the need for parental consent. Between June 2011 and June 2014, inborn ELBW infants were included in this prospective observational study if they met the following conditions: a diagnosis of respiratory distress syndrome (RDS), requiring endotracheal intubation at birth or failing nasal continuous positive airway pressure (CPAP) within 24 hours of life; electively HFOV ventilated and receiving surfactant treatment and directly extubated from HFOV.

**HFOV strategy**

HFOV is actually the elective modality of ventilation in preterm newborns with GA ≤27 weeks and/or ELBW infants in our NICU, as a result of our previous randomised controlled trial comparing the effects of HFOV \textit{versus} CMV.\textsuperscript{21} HFOV was delivered by a Dräger Babylog 8000 \textit{plus} ventilator (Dräger, Lubeck, Germany) with an ‘optimum lung volume strategy’ prior to surfactant administration, recruiting collapsed alveoli using oxygenation with a FiO\textsubscript{2} target ≤0.25 as an indirect parameter for lung volume.\textsuperscript{17}

Ventilation was started at a MAP of 10 cm H\textsubscript{2}O, a frequency of 10 Hz, and an amplitude of 30\%, increased if necessary until the infant’s chest was seen to be visibly vibrating. The FiO\textsubscript{2} was initially set to ensure adequate oxygen saturation (SpO\textsubscript{2} 90\%–95\%). If the FiO\textsubscript{2} was >0.25, the MAP was increased by 1–2 cm H\textsubscript{2}O every 2–5 min until FiO\textsubscript{2} reached ≤0.25. The recruitment was stopped if oxygenation no longer improved or there were signs of lung hyperinflation (capillary refill time >3 s and/or hypotension). This approach provides a more effective means to recruit and protect acutely injured lungs.\textsuperscript{17} Surfactant was administered at the end of the recruitment procedure. Transcutaneous PaO\textsubscript{2} of CO\textsubscript{2} (TcPCO\textsubscript{2}) and/or PaCO\textsubscript{2} were managed by adjustment of the oscillatory amplitude and then of the

**Figure 1** Infant flow diagram during the study period. CPAP, continuous positive airway pressure; HFOV, high-frequency oscillatory ventilation.
The goals of respiratory management were to maintain blood gas values of: pH 7.30–7.45, PaCO₂ and/or TcPCO₂ 45–55 mm Hg, PaO₂ and/or transcutaneous PaO₂ of O₂ (TcPO₂) 50–70 mm Hg and SpO₂ 90%–95%. All patients received a loading dose of caffeine (20 mg/kg) immediately after admission to the NICU, then maintenance therapy and Remifentanil by continuous intravenous infusion at a dose of 0.075 μg/kg/min to provide analgesia during HFOV while preserving spontaneous respiratory activity. Doxapram was not used during the study period as per our departmental protocols.

**Weaning and extubation criteria**

HFOV ventilation was managed to ensure to patients the lowest possible MAP, amplitude and FiO₂ in order to minimise ventilator-induced lung injury. Reduction in MAP was gradually accomplished following oxygenation and lung expansion estimated by chest radiographs. FiO₂ was adjusted to maintain adequate oxygenation. Reduction of amplitude was gradually accomplished following TcPCO₂ and/or PaCO₂ values. Extubation was attempted when the neonate’s condition remained stable for at least 6 hours, receiving ventilation with MAP ≤6 cm H₂O and FiO₂ ≤0.25. At that point in time a FiO₂ ≥0.25 and ≤0.30 was acceptable, to ensure that the extubation was not delayed by small fluctuations in oxygen need.

After extubation, all the patients were supported by nasal CPAP at 6–8 cm H₂O using short binasal prongs of appropriate size while nasal ventilation was not administered. Extubation failure was defined as clinical deterioration requiring reintubation during the following 7 days. All data refer only to the first extubation attempt in the studied neonates.

The indications for reintubation were: (1) repeated episodes of apnoea defined as >4 episodes of apnoea per hour (or >2 episodes of apnoea per hour when ventilation with bag and mask was required); (2) hypoxia defined as FiO₂ >0.50 to maintain SpO₂ 90%–95% for more than 2 hours despite 8 cm H₂O of CPAP; (3) development of respiratory acidosis indicated by two consecutive blood gases with PaCO₂ ≥65 mm Hg and pH <7.20.

**Data collection**

Demographic data on patient and maternal characteristics were collected from each patient. Data were collected on MAP, FiO₂, amplitude, frequency, DCO₂, tidal volume HFOV (VT), TcPO₂, TcPCO₂ at start of ventilation and at the time of extubation attempt. Finally, data on MAP and FiO₂ were collected at the end of HFOV recruitment procedure, immediately prior to surfactant administration. The number of patients failing extubation was collected, including the main reason for failure and the time of reintubation. Weight and day of life at extubation, duration of mechanical ventilation and O₂-therapy during the hospital stay, requirement of additional doses of surfactant and development of BPD (O₂-dependence at 36 weeks of postmenstrual age) were also reported for each patient.

**Statistical analysis**

Values were expressed as mean and SD or median and range for continuous variables or absolute frequency and percentages for categorical variables. Continuous variables were compared with parametric (Student’s t test) or non-parametric (Mann Whitney U test) tests as appropriate. Categorical variables were compared by using a two-tailed Fisher’s exact test. A 2-tailed value of p<0.05 was considered significant. Data were analysed using commercial statistical software (Graphpad Prism V.5.0a; Chicago, Illinois, USA).

In order to evaluate the association between the successful extubation and each explanatory variable, a univariable analysis was performed using a logistic
regression model by including one variable at a time. The independent variables found to be significant in the univariable analyses (p≤0.05) were included in the multivariable model. A likelihood ratio test was used to compare the suitability of the models and to select the most appropriate model. Statistical analyses were done with Stata V.2013 software (Stata Statistical Software: Release 13, College Station, Texas, USA).

RESULTS
During the study period, 108 ELBW infants with RDS required elective HFOV within 24 hours of life and were directly extubated from HFOV (figure 1). Extubation was attempted at a median (range) age of 4 (1–53) days (table 1). All the comparisons were made between newborns successfully extubated (Extubation Success Group) and newborns failing the extubation attempt (Extubation Failure Group). The percentage of newborns successfully extubated was 83%. The only significant differences between the two groups were the higher percentage of males in the neonates who failed extubation and their lower GA (table 1).

Table 1

| Extubation Success Group | Extubation Failure Group | P values |
|--------------------------|--------------------------|----------|
| MAP (cm H₂O)             | 10.2±1.1                 | 10.2±1.0 | 0.94 |
| FiO₂                     | 0.40±0.17                | 0.48±0.24 | 0.08 |
| Amplitude (%)            | 59±33                    | 56±32    | 0.72 |
| Frequency (Hz)           | 9.6±1.0                  | 9.7±0.8  | 0.69 |
| V₁ (mL/kg)               | 1.6±0.6                  | 1.5±0.5  | 0.51 |
| DCO₂ (mL²/kg²/s)         | 25±15                    | 25±10    | 1    |
| TcPO₂ (mm Hg)            | 53±12                    | 50±8     | 0.31 |

Values expressed as mean±SD.

Table 2 Ventilator settings, ventilation and transcutaneous blood gas values at baseline, presurfactant and at extubation time

| Ventilator Settings | Extubation Success Group | Extubation Failure Group | P values |
|---------------------|--------------------------|--------------------------|----------|
| MAP (cm H₂O)        | 10.2±1.1                 | 10.2±1.0                 | 0.94     |
| FiO₂                | 0.40±0.17                | 0.48±0.24                | 0.08     |
| Amplitude (%)       | 59±33                    | 56±32                    | 0.72     |
| Frequency (Hz)      | 9.6±1.0                  | 9.7±0.8                  | 0.69     |
| V₁ (mL/kg)          | 1.6±0.6                  | 1.5±0.5                  | 0.51     |
| DCO₂ (mL²/kg²/s)    | 25±15                    | 25±10                    | 1        |
| TcPO₂ (mm Hg)       | 53±12                    | 50±8                     | 0.31     |

Values expressed as mean±SD.

DCO₂, coefficient of gas transport; MAP, mean airways pressure; TcPCO₂, transcutaneous PaO₂ of CO₂; TcPO₂, transcutaneous PaO₂ of O₂.

VT: tidal volume HFOV.
Regarding the ventilator setting at the baseline, no significant differences were observed between the two groups (table 2). Prior to surfactant administration, the neonates of the Extubation Success Group received ventilation with a significantly higher MAP and lower $\text{FiO}_2$ ($p=0.02$ and $p<0.001$, respectively) in comparison to the newborns of the Extubation Failure Group (table 2). At extubation, there were no differences in MAP, $\text{FiO}_2$, amplitude or frequency between infants who were successfully extubated and those who failed extubation (table 2).

Finally, the neonates of Extubation Failure Group required treatment with additional doses of surfactant more frequently than infants of Extubation Success Group ($p=0.006$) and received a significantly longer period of mechanical ventilation ($p=0.02$) (table 3). Although the neonates of the Extubation Failure Group had a higher percentage of BPD, the difference was not statistically significant (table 3).

Multivariable analysis showed that GA (OR 1.71; 95% CI 1.04 to 2.08) and higher MAP prior to surfactant administration (OR 1.51; 95% CI 1.06 to 2.15) were associated with successful extubation (table 4).

### DISCUSSION

In comparison to the only experience reported on the successful extubation rates directly from HFOV by van Velzen et al.\textsuperscript{20}, referring to a heterogeneous population of 214 preterm infants and including only 68 neonates with a birth weight $\leq 1000\text{g}$, our report provides more detailed data on the extubation process during HFOV in a large cohort of ELBW infants. Moreover, our study evaluated the success or failure of the extubation attempt over a longer period of time (within 7 days), compared with the usually shorter time windows ($\leq 48$ or $\leq 72$ hours after extubation). This is particularly important, considering the recent remarks by Giaccone et al.,\textsuperscript{13} which showed that in studies predominately enrolling ELBW infants, rates of extubation success were negatively associated with the duration of observation. By relying on shorter windows of observation, studies enrolling a larger proportion of small infants may therefore underestimate the true rate of reintubation. In fact, the reintubation rate did not appear to plateau even after a week of observation, indicating that longer periods may be necessary to adequately capture this outcome in ELBW infants.\textsuperscript{13}

In our experience, neonates of the Extubation Failure Group prior to surfactant administration received ventilation with a significantly lower MAP ($p<0.05$) and a significantly higher $\text{FiO}_2$ ($p<0.001$) in comparison respect to the newborns of the Extubation Success Group (table 2). A lower MAP prior surfactant was confirmed by multivariable analysis as an independent risk factor for extubation failure (tables 2 and 4). This occurred despite our protocol of optimal lung volume strategy aiming to fully recruit the lung before surfactant therapy, increasing step-by-step MAP until the target $\text{FiO}_2$ of 0.25 had been reached: in case of the neonates who failed extubation, surfactant had been administered before achieving optimal lung recruitment. Even though they were affected by a more severe RDS, as demonstrated by the higher baseline $\text{FiO}_2$ in comparison to the neonates who experienced successful extubation, the importance of fully recruiting the lung before surfactant administration should be taken into account, because of the significant association of optimal lung volume strategy with better respiratory outcomes.\textsuperscript{17} Neonates of the Extubation Failure Group received in fact more frequently additional surfactant doses (table 3).

When compared with the only study reporting the feasibility of weaning and direct extubation from HFOV in ELBW infants,\textsuperscript{20} our data showed similar rates of successful extubation: 88% within 72 hours and 85% within 7 days after the extubation attempt, versus 81% within 48 hours only, respectively. More importantly, our rates of extubation failure are lower than those recently reported by Giaccone et al. in a recent systematic review on the definition of extubation success in very premature infants.\textsuperscript{13} In the multivariable linear regression analysis, median subject’s birth weight $\leq 1000\text{g}$ was found to be an effect modifier ($p=0.03$) in the association between duration of postextubation observation and rate of reintubation. After stratifying the analysis for this variable, the authors found that in studies of infants with median birth weight $\leq 1000\text{g}$, the reintubation rate

### Table 3  
| Mortality and respiratory outcomes | Extubation Success Group | Extubation Failure Group | P values |
|-----------------------------------|-------------------------|--------------------------|---------|
| Mortality                         | 11 (12)                 | 1 (5)                    | 0.68    |
| >1 dose of surfactant             | 19 (21)                 | 10 (56)                  | 0.006   |
| Total ventilator, days            | 8 (0.3–137)             | 16 (0.5–84)              | 0.02    |
| Total oxygen, days                | 31 (0–200)              | 41 (0.4–193)             | 0.18    |
| BPD*                              | 16/79 (20)              | 6/17 (35)                | 0.20    |

Values expressed as median (range) and number (per cent). *Data are referred to >36 weeks postmenstrual age survivors babies only. BPD, bronchopulmonary dysplasia.

### Table 4  
| Risks factors for extubation outcome: multivariable analysis | Extubation Success Group | OR     | 95% CI              | P values |
|--------------------------------------------------------------|--------------------------|--------|---------------------|---------|
| Gestational age (weeks)                                      | 1.71                     | 1.04 to 2.08 | 0.03   |
| Male                                                         |                          | 3.08   | 0.85 to 11.2        | 0.09    |
| MAP (cm H$_2$O) presurfactant                               | 1.51                     | 1.06 to 2.15 | 0.02   |
| $\text{FiO}_2$ presurfactant                               | 0.06                     | 0.00 to 1.57 | 0.09   |
| >1 dose of surfactant                                       | 0.31                     | 0.09 to 1.16 | 0.08   |
| $\text{FiO}_2$ fraction of inspired oxygen; MAP, mean airways pressure. | | | |
increased significantly with longer duration of observation (P=0.001). In particular, the mean reintubation rate in the newborns with median birth weight ≤1000 g increased from 25% at 72 hours to 35% at 168 hours, with the latter result being more than double of that reported in our experience (17%). It is, however, necessary to keep in mind that by prolonging the observation period, the chances of reintubation for a different cause of respiratory failure (ie, sepsis) increase. In our experience, no newborn who failed extubation had an episode of suspected or confirmed sepsis during the 7-day period after extubation.

In our study, the neonates failing extubation had significantly lower GA compared with infants successfully extubated, with the lower GA being an independent risk factor for extubation failure in the multivariable analysis (tables 1 and 4). Apnoea was the main reason for reintubation (39% of cases) stressing the important role of the central inspiratory drive in determining the premature infant’s ability to maintain adequate, independent ventilation. The use of other non-invasive respiratory support, alternatives to CPAP alone in the postextubation period (ie, nasal intermittent mandatory ventilation and/or bilevel CPAP), may be a better strategy to overcome this problem. Recently, Buzzella et al showed that in preterm infants with residual lung disease nasal CPAP in the range of 7–9 cm H₂O it was more effective in reducing extubation failure than a range of 4–6 cm H₂O. These findings suggest: the need for higher distending pressure postextubation to obtain better oxygenation with a more stable lung volume and reduced pulmonary shunt in the more immature infants who are still oxygen-dependent; the improved oxygenation and lung volume stability may have also attenuated central and obstructive apnoea. Hypoxia and hypercapnia accounted for most of extubation failure attempts after the first 24 hours (8 out of 13, 61%): a recruitment manoeuvre to try to adequately open the lung could play an important role in preventing extubation failure, as suggested by the results of multivariable analysis. Importantly, we used MAP ≤6 cm H₂O and FiO₂ ≤0.25 as criteria to attempt extubation. Using these lower setting in comparison to those adopted by van Velzen may improve the success rate of extubation but it may also prolong the time on the ventilator. Future studies could evaluate if extubation at higher HFOV settings in ELBW infants could result in similar rates of extubation failure while reducing the ventilation time.

Although our study suggests that direct extubation from HFOV is feasible in ELBW infants, there are some limitations and important questions that remain to be answered. First of all, the small number of ELBW infants failing extubation could limit the power to detect differences between groups and might have affected the accuracy of our estimates. Moreover, higher level of CPAP postextubation (7–9cm H₂O) or other non-invasive respiratory support, such as synchronised nasal IPPV or nasal HFOV, could be used to improve the success rate of extubation in ELBW infants.

Future randomised controlled trials will be needed to address these questions, also taking into account the possible effects on long-term respiratory outcomes.

In conclusion, this study shows that in ELBW infants electively HFOV ventilated with an open lung strategy, direct extubation from HFOV at MAP ≤6 cm H₂O with FiO₂ ≤0.25 is feasible. Our extubation success rate (83%) is comparable to and/or higher than success rates reported for extubation from CMV in this very vulnerable class of infants.

Acknowledgements We thank the families of the patients for their understanding and cooperation and the nursing staff for their invaluable support.

Contributors MT designed the study, collected the data, analysed the data and wrote the first and final drafts of the manuscript. AL carried out the data collection and the literature search, assisted with the analysis and provided significant edits to the manuscript. CT and CA carried out the data collection and drafted the initial manuscript. ET carried out the data collection and the initial analyses, reviewed and revised the manuscript. FS, VR MC and PC carried out the data collection, the literature search, reviewed and revised the manuscript. VD A, GB and CR carried out the data collection, the literature search, reviewed and made significant edits to the manuscript. RP carried out statistical analysis G V conceptualised and designed the study and critically reviewed the manuscript. All authors read and approved the submission of this version of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent Not required.

Ethics approval This study was approved by the Ethics Committee of the Department of Pediatrics of Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy—Università Cattolica del Sacro Cuore.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Finer NN, Carlo WA, Walsh MC, et al. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010;362:1970–9.
2. Morley CJ, Davis PG, Doyle LW, et al. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 2008;359:705–8.
3. Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010;126:443–56.
4. Miller JD, Carlo WA. Pulmonary complications of mechanical ventilation in neonates. Clin Perinatal 2008;35:273–81.
5. Garland JS. Strategies to prevent ventilator-associated pneumonia in neonates. Clin Perinatal 2010;37:629–43.
6. Walsh MC, Morris BH, Wragge LA, et al. Extremely low birthweight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. J Pediatr 2005;146:798–804.
7. Sant’Anna GM, Keszler M. Weaning infants from mechanical ventilation. Clin Perinatal 2012;39:543–62.
8. Vento G, Tortorolo L, Zecca E, et al. Spontaneous minute ventilation is a predictor of extubation failure in extremely-low-birth-weight infants. J Matern Fetal Neonatal Med 2004;15:147–54.
9. Dimitriou G, Greerough A, Eno A, et al. Prediction of extubation failure in preterm infants. Arch Dis Child Fetal Neonatal Ed 2002;86:32F–5.
10. Szyniszewicz M, Vidyasagar D, Gadzinowski J. Predictors of successful extubation of preterm low-birth-weight infants with respiratory distress syndrome. Pediatr Crit Care Med 2005;6:44–9.
11. Kamlin CO, Davis PG, Morley CJ. Predicting successful extubation of very low birthweight infants. *Arch Dis Child Fetal Neonatal Ed* 2006;31:F180–F183.

12. Stefanescu BM, Murphy WP, Hansell BJ, et al. A randomized, controlled trial comparing two different continuous positive airway pressure systems for the successful extubation of extremely low birth weight infants. *Pediatrics* 2003;112:1031–8.

13. Giaccone A, Jensen E, Davis P, et al. Definitions of extubation success in very premature infants: a systematic review. *Arch Dis Child Fetal Neonatal Ed* 2014;99:F124–7.

14. Manley BJ, Doyle LW, Owen LS, et al. Extubating Extremely Preterm Infants: Predictors of Success and Outcomes following Failure. *J Pediatr* 2016;173:45–9.

15. Cools F, Offringa M, Askie LM. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. *Cochrane Database Syst Rev* 2015;3:CD000104.

16. Courtney SE, Durand DJ, Asselin JM, et al. High-frequency oscillatory ventilation versus conventional ventilation for very-low-birth-weight infants. *N Engl J Med* 2002;347:643–52.

17. Tana M, Zecca E, Tirone C, et al. Target fraction of inspired oxygen during open lung strategy in neonatal high frequency oscillatory ventilation: a retrospective study. *Minerva Anestesiol* 2012;78:151–9.

18. Johnson AH, Peacock JL, Greenough A, et al. High-frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. *N Engl J Med* 2002;347:633–42.

19. Clark RH, Gerstmann DR, Null DM, et al. Prospective randomized comparison of high-frequency oscillatory and conventional ventilation in respiratory distress syndrome. *Pediatrics* 1992;89:5–12.

20. van Velzen A, De Jaegere A, van der Lee J, et al. Feasibility of weaning and direct extubation from open lung high-frequency ventilation in preterm infants. *Pediatr Crit Care Med* 2009;10:71–5.

21. Vento G, Matassa PG, Ameglio F, et al. HFOV in premature neonates: effects on pulmonary mechanics and epithelial lining fluid cytokines. A randomized controlled trial. *Intensive Care Med* 2005;31:463–70.

22. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. *N Engl J Med* 2006;354:2112–21.

23. Giannantonio C, Sammartino M, Valente E, et al. Remifentanil analgesedation in preterm newborns during mechanical ventilation. *Acta Paediatr* 2009;98:1111–5.

24. Buzzella B, Claire N, D’Ugard C, et al. A randomized controlled trial of two nasal continuous positive airway pressure levels after extubation in preterm infants. *J Pediatr* 2014;164:46–51.

25. Gizzi C, Montecchia F, Panetta V, et al. Is synchronised NIPPV more effective than NIPPV and NCPAP in treating apnoea of prematurity (AOP)? A randomised cross-over trial. *Arch Dis Child Fetal Neonatal Ed* 2015;100:F17–23.

26. Zhu XW, Zhao JN, Tang SF, et al. Noninvasive high-frequency oscillatory ventilation versus nasal continuous positive airway pressure in preterm infants with moderate-severe respiratory distress syndrome: A preliminary report. *Pediatr Pulmonol* 2017;52:1038–42.